Clinical review report: Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) (Recordati Rare Diseases Canada Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of cysteamine 3.8 mg/mL (CH 0.55% by weight) ophthalmic solution (Cystadrops) for the treatment of corneal cystine crystals deposits in adults and children from two years of age with cystinosis
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
July 2019, 2019
|
| Edition: | Version: final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of cysteamine 3.8 mg/mL (CH 0.55% by weight) ophthalmic solution (Cystadrops) for the treatment of corneal cystine crystals deposits in adults and children from two years of age with cystinosis |
|---|---|
| Physical Description: | 1 PDF file (84 pages) illustration |